Trials / Completed
CompletedNCT07526961
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Retrospective Hospitals' Database Analysis to Evaluate Efficacy and Safety of Double Immunochemotherapy in First-Line Non-Small Cell Lung Cancer in Real Clinical Practice in Poland
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will review medical records from hospitals in Poland to describe the demographics and baseline clinical characteristics of adults with advanced non-small cell lung cancer who received first-line nivolumab plus ipilimumab with chemotherapy in routine care between 01 January 2023 and 31 December 2023. The study will also describe treatment patterns and clinical outcomes, associated with immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Nivolumab + Ipilimumab + Chemotherapy | As per product label |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-01-20
- Completion
- 2026-01-20
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Locations
1 site across 1 country: Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07526961. Inclusion in this directory is not an endorsement.